Addressing the Inhibitor
Eliminating inhibitor: Immune tolerance
Started on daily infusion of FVIII, in 2 months inhibitor is 5 BU, FVIII activity still <1%
Trial of rituximab results in eradication of the inhibitor and return to baseline FVIII of 3%
Treatment of bleeding episodes during IT
By-passing product